Back to top
more

BioLineRx (BLRX)

(Delayed Data from NSDQ)

$0.66 USD

0.66
186,723

+0.02 (2.56%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $0.65 -0.01 (-0.99%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

BioLineRx Ltd. [BLRX]

Reports for Purchase

Showing records 1 - 20 ( 201 total )

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 1

02/29/2024

Company Report

Pages: 7

CheMo4METPANC Phase 2 Trial Kicks Off With First Patient Dosing in Expanded Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 2

12/21/2023

Daily Note

Pages: 5

Dosing Commences in Phase 1 Motixafortide Trial in Sickle Cell Disease; Initial Data in 2H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 3

11/20/2023

Company Report

Pages: 7

3Q23 Results; Motixafortide Building Early Commercial Footprint and Beyond; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 4

10/13/2023

Company Report

Pages: 6

APHEXDA Chalks Up Another Strategic Win; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 5

09/29/2023

Company Report

Pages: 6

Combination Trial in 1L PDAC Raises Motixafortide''s Profile; Randomized Phase 2 Enrolling

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 6

09/15/2023

Company Report

Pages: 7

Welcome APHEXDA to the Market; BLRX''s First FDA Approval; Price Target Upped to $21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 7

08/30/2023

Company Report

Pages: 7

2Q23 Results; Motixafortide Pre-Launch Activities Ramp Up With Imminent PDUFA Date

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 8

05/24/2023

Company Report

Pages: 7

1Q23 Results; Commercial Plans Solidify as September 9, 2023, Marks the "BioLine" for PDUFA Target Date

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 9

03/22/2023

Company Report

Pages: 8

2022 Results; U.S. Commercialization Team Finalized for APHEXDA; PDUFA Date September 9, 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 10

11/15/2022

Company Report

Pages: 7

3Q22 Results; APHEXDA Commercial Readiness Activities Continue Ahead of PDUFA September 9, 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 11

09/28/2022

Company Report

Pages: 7

U.S. Commercial Strategy For APHEXDA (Motixafortide) Begins to Mobilize; Launch Anticipated in 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 12

05/12/2022

Company Report

Pages: 6

1Q22 Results; Imminent Motixafortide NDA Submission Mid-2022; Potential Commercialization in 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 13

03/16/2022

Company Report

Pages: 6

2021 Results; Focus Shifts Toward Pre-Launch Activities; NDA Submission on Track for Mid-2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 14

01/18/2022

Company Report

Pages: 6

NDA Submission Imminent as Motixafortide Partnership Discussions Continue

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 15

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for BLRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 16

08/18/2021

Company Report

Pages: 7

2Q21 Results; Visions of a Forthcoming BLA and a Likely Partnership Dancing in Our Heads

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 17

05/27/2021

Company Report

Pages: 7

1Q21 Results; Motixafortide Marches Towards NDA Filing in 1H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 18

05/05/2021

Company Report

Pages: 6

GENESIS Phase 3 Data Details Pretty Darn Impressive; NDA Expected in 1H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 19

02/23/2021

Company Report

Pages: 9

2020 Results; First NDA in Sight; We Believe Also a Meaningful Partnership; Target Adjusted to $19

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 20

12/16/2020

Company Report

Pages: 8

COMBAT Gives a Big Bloody Nose to Pancreatic Cancer; Target Increased to $22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party